2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis

期刊论文
出版模式：

开放获取
发表日期：

2024年5月16日

查看全文

Hirotoshi Iihara,
Masakazu Abe,
Makoto Wada,
Keiko Iino,
Tatsuo Akechi,
Chiyo K. Imamura,
Ayako Okuyama,
Keiko Ozawa,
Yong-Il Kim,
Hidenori Sasaki,
Eriko Satomi,
Masayuki Takeda,
Ryuhei Tanaka,
Takako Eguchi Nakajima,
Naoki Nakamura,
Junichi Nishimura,
Mayumi Noda,
Kazumi Hayashi,
Takahiro Higashi,
Narikazu Boku,
Koji Matsumoto,
Yoko Matsumoto,
Kenji Okita,
Nobuyuki Yamamoto,
Kenjiro Aogi

摘要

Background

The Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis 2023 was extensively revised to reflect the latest advances in antineoplastic agents, antiemetics, and antineoplastic regimens. This update provides new evidence on the efficacy of antiemetic regimens.

Methods

Guided by the Minds Clinical Practice Guideline Development Manual of 2017, a rigorous approach was used to update the guidelines; a thorough literature search was conducted from January 1, 1990, to December 31, 2020.

Results

Comprehensive process resulted in the creation of 13 background questions (BQs), 12 clinical questions (CQs), and three future research questions (FQs). Moreover, the emetic risk classification was also updated.

Conclusions

The primary goal of the present guidelines is to provide comprehensive information and facilitate informed decision-making, regarding antiemetic therapy, for both patients and healthcare providers.